表紙
市場調查報告書
商品編碼
1071816

全球疫苗銷售市場分析(2022-2032):按適應症、給藥途徑、類型、分銷渠道、年齡組、按地區/主要國家、主要公司、新冠狀病毒從傳染病(COVID- 19)

Vaccine Sales Market Report 2022-2032: Forecasts by Indication, by Route of Administration, by Type, by Distribution Channel, by Age Group, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

出版日期: | 出版商: Visiongain Reports Ltd. | 英文 622 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告分析全球疫苗銷售市場,並分析產品概況、基本結構/市場最新情況、主要促進/抑制因素、估計/預測市場規模(2022-2032)、詳細趨勢根據適應症、給藥途徑、類型、分銷渠道、年齡組和地區、主要國家、主要公司概況、COVID-19的影響和恢復情況等。

圖表示例

目錄

第 1 章分析概述

第 2 章執行摘要

第 3 章行業考慮

  • 新型冠狀病毒感染 (COVID-19):對疫苗銷售市場的影響
  • 疫苗銷售市場的當前趨勢
  • 市場促進因素
    • 對免疫計劃和政府支持的興趣增加
    • 加大疫苗研發投入
    • 加大企業積極性,加強疫苗研發
    • 傳染病高發
    • 疫苗接種技術進步
    • 急需免疫
    • 強大的研發支撐著強大的供應
  • 市場抑制因素
    • 贖回補償不足
    • 疫苗研發成本高
    • 疫苗生產週期長短
    • 嚴格的政府審批規定
    • 獲得疫苗的機會不足
    • 產品召回
  • 市場機會
    • 新興市場的高增長前景
    • 對治療性疫苗的興趣日益濃厚
    • 佐劑在疫苗中的應用
    • 政府對未來疫苗研發的支持
  • SWOT分析
  • PEST 分析

第 4 章全球疫苗銷售市場分析

  • 全球市場展望
  • 估計和預測市場規模
    • COVID-19 之前的市場情景
    • COVID-19 之後的市場情景(V 型/U 型/W 型/L 型複蘇分析)

第 5 章全球疫苗銷售市場分析:按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 市場規模估計和預測:按地區

第 6 章全球疫苗銷售市場分析:按適應症

  • 細分概覽
  • 肺炎鏈球菌
  • 輪狀病毒
  • 流感
  • 肝炎
  • COVID-19(新型冠狀病毒感染)
  • 麻疹
  • 腮腺炎/水痘
  • 傷寒
  • 腦膜炎奈瑟菌
  • DPT
  • 市場規模估計和預測:按指示

第 7 章全球疫苗銷售市場分析:按管理途徑

  • 細分概覽
  • 肌肉注射
  • 皮下
  • 經口
  • 全球市場規模的估計和預測:按管理途徑

第 8 章全球疫苗銷售市場分析:按類型

  • 細分概覽
  • 滅活□□疫苗
  • 減毒活疫苗
  • 類毒素疫苗
  • 轉基因/結合/亞單位疫苗
  • 市場規模估計和預測:按類型

第 9 章全球疫苗銷售市場分析:按分銷渠道

  • 細分概覽
  • 醫院/零售藥店
  • 政府附屬供應商
  • 市場規模估計和預測:按分銷渠道

第 10 章全球疫苗銷售市場分析:按年齡組

  • 細分概覽
  • 兒童
  • 成人
  • 市場規模估計和預測:按年齡組

第 11 章北美疫苗銷售市場

  • 簡介
  • 市場預測:按國家分類(2022-2032 年)
  • 市場預測:按指示
  • 市場預測:按管理途徑
  • 市場預測:按類型
  • 市場預測:按分銷渠道
  • 市場預測:按年齡組
  • 美國市場 (2022-2032)
    • 簡介
    • 市場收入 (2022-2032)
    • COVID-19 影響的恢復情景(V 形/U 形/W 形/L 形)
  • 加拿大市場 (2022-2032)

第 12 章歐洲疫苗銷售市場

  • 簡介
  • 市場預測:按國家分類(2022-2032 年)
  • 市場預測:按指示
  • 市場預測:按管理途徑
  • 市場預測:按類型
  • 市場預測:按分銷渠道
  • 市場預測:按年齡組
  • 德國市場 (2022-2032)
  • 英國市場 (2022-2032)
  • 法國市場(2022-2032)
  • 義大利市場 (2022-2032)
  • 西班牙市場(2022-2032)
  • 俄羅斯市場(2022-2032)
  • 其他歐洲國家的市場 (2022-2032)

第 13 章亞太疫苗銷售市場

  • 簡介
  • 市場預測:按國家分類(2022-2032 年)
  • 市場預測:按指示
  • 市場預測:按管理途徑
  • 市場預測:按類型
  • 市場預測:按分銷渠道
  • 市場預測:按年齡組
  • 日本市場 (2022-2032)
  • 中國市場(2022-2032)
  • 印度市場 (2022-2032)
  • 澳大利亞市場 (2022-2032)
  • 其他亞太國家的市場 (2022-2032)

第 14 章拉丁美洲疫苗銷售市場

  • 簡介
  • 市場預測:按國家分類(2022-2032 年)
  • 市場預測:按指示
  • 市場預測:按管理途徑
  • 市場預測:按類型
  • 市場預測:按分銷渠道
  • 市場預測:按年齡組
  • 巴西市場 (2022-2032)
  • 墨西哥市場 (2022-2032)
  • 其他拉丁美洲國家的市場 (2022-2032)

第 15 章中東/非洲疫苗銷售市場

  • 簡介
  • 市場預測:按國家分類(2022-2032 年)
  • 市場預測:按指示
  • 市場預測:按管理途徑
  • 市場預測:按類型
  • 市場預測:按分銷渠道
  • 市場預測:按年齡組
  • 海灣合作委員會 (GCC) 國家市場 (2022-2032)
  • 南非市場 (2022-2032)
  • 其他中東國家的市場 (2022-2032)

第 16 章公司簡介

  • Bavarian Nordic
    • 快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 最新趨勢(至 2021 年 12 月)
  • Bharat Biotech
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • J&J
  • Merck Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • AstraZeneca PLC
  • Sinopharm
  • SINOVAC
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Co., Ltd.

第 17 章結論/建議

目錄
Product Code: PHA1165

Title:
Vaccine Sales Market Report 2022-2032
Forecasts by Indication (Pneumococcal, Rotavirus, Influenza, Hepatitis, COVID-19, Measles, Mumps & Varicella, Typhoid, Meningococcal, DPT, Others), by Route of Administration (Intramuscular, Subcutaneous, Oral), by Type (Inactivated, Live Attenuated, Toxoid, Recombinant/Conjugate/Subunit), by Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others), by Age Group (Paediatrics, Adults) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

Use of Adjuvants in Vaccines to Offer Lucrative Growth Prospects

The growing usage of integrated unit vaccinations is propelling the adjuvant industry forward. The need for different adjuvants is increasing as consumption rises. More development is projected in the next years, which will raise the need for adjuvants. The market is predicted to develop at a modest pace, owing to the rising use of biologics and biosimilars, as well as increased R&D in vaccines throughout the globe. Unmet demand for specialised vaccinations, higher government immunisation recommendations, technical advancements, and greater usage of combination and synthetic vaccines are all factors that contribute to the development of the adjuvants vaccine market.

Growing Vaccination Awareness to Boost Market Growth

Over the past years, national and local bodies have taken efforts to aware public of benefits of vaccine immunization. The media plays an important role in spreading awareness among the general public regarding pros and cons of vaccine immunization. With the growing level of medica coverage in rural parts of developing and under-developed economies, the market for live vaccines is anticipated to witness lucrative opportunities over the forecast period.

What are the Growth Drivers for Vaccine Sales Market?

  • Rising Focus and Government Support on Immunization Programs
  • Growing Investment in Vaccine Development
  • Increasing Company Initiatives to Enhance Vaccine R&D
  • High Prevalence of Infectious Diseases
  • Technological Advancements in Vaccine Administration
  • Rapid Need of Immunization
  • Strong Supply Backed Up by Robust R&D to Drive the Market

What are the Challenges for Vaccine Sales Market?

  • Inadequate Reimbursement Coverage
  • High Cost of Vaccine Development
  • Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
  • Stringent Government Regulations for Approval

What are the Market Opportunities?

  • High Growth Prospects in Emerging Markets
  • Focus on Therapeutic Vaccines
  • Use of Adjuvants in Vaccines
  • Government Support for Future Vaccine R&D

Long Timelines of Vaccine Manufacturing Projected to Hinder Vaccines Market Growth

Vaccine development is seen as an expensive, difficult, and time-consuming process because to the intricacy of manufacturing and accompanying processes, which may take up to 10-15 years. Due to the endless combinations of biological ingredients, microorganisms, equipment employed, ambient conditions, and culture stages, results may vary greatly throughout manufacturing. Furthermore, the reagents and procedures needed to monitor culture parameters add to the process' complexity, prolonging production times.

Furthermore, product approvals from regulatory bodies take longer since the authorities evaluate the product's quality and effectiveness, as well as the manufacturing process. After the producers show enough pre-clinical evidence on the vaccines' safety to confirm the vaccines' action in people, the vaccines start clinical trials. Even after approval, each year, vaccination batches are evaluated for safety and stability to guarantee compliance with regulatory requirements. Furthermore, the longer the deadlines, the greater the production cost, which restricts new manufacturers from entering the market, stifling growth.

Discover how to stay ahead

Our 620+ page report provides 640+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. <>Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccine Sales Market. See how to exploit the opportunities.

Forecasts to 2032 and other analyses reveal the commercial prospects.

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter's Five Forces, SWOT Analysis, product profiles and commercial developments.

Discover sales predictions for the world market and sub-markets

    Indication
  • Pneumococcal
  • Rotavirus
  • Influenza
  • Hepatitis
  • COVID-19
  • Measles
  • Mumps & Varicella
  • Typhoid
  • Meningococcal
  • DPT
  • Others

Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral

Type

  • Inactivated
  • Live Attenuated
  • Toxoid
  • Recombinant/Conjugate/Subunit

Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Age Group

  • Pediatrics
  • Adults

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Leading companies and the potential for market growth

Overall world revenue for Vaccine Sales Market will surpass $xx billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for established firms and those seeking to enter the market- including company profiles for 20 of the major companies involved in the Vaccine Sales market. Some of the companies profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited among other prominent players.

How the Vaccine Sales Market report helps you

In summary, our 620+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for Vaccine Sales Market, with forecasts for 11 indications, 3 route of administration, 4 types, 3 distribution channel, and 2 age groups , each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2032 for 5 regional and 20 key national markets- See forecasts for the Vaccine Sales market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, South Korea, and South-East Asia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 20 of the companies involved in the Vaccine Sales Market. Some of the company's profiled in this report include Bavarian Nordic, Bharat Biotech, CSL Limited, Daiichi Sankyo Co., Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J&J, Merck Co., Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., Novavax, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Sinopharm, SINOVAC, and Takeda Pharmaceutical Company Limited, among other prominent players.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Vaccine Sales Market and leading companies. You will find data, trends, and predictions.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Vaccine Sales Market
  • 1.1 Vaccine Technologies
    • 1.1.1 Live-Attenuated Vaccines
    • 1.1.2 Inactivated Vaccines
    • 1.1.3 Toxoid Vaccines
    • 1.1.4 Subunit Vaccines
    • 1.1.5 Virus-Like Particles (VLP) Vaccines
    • 1.1.6 Bacterial Outer Membrane Vesicle (OMV) Vaccines
  • 1.2 Platform-based Vaccines
    • 1.2.1 DNA Vaccines
    • 1.2.2 mRNA Vaccines
    • 1.2.3 Viral Vector Vaccines
  • 1.3 Vaccine Sales Market Definition
  • 1.4 Why You Should Read This Report
  • 1.5 What This Report Delivers
  • 1.6 Key Questions Answered By This Analytical Report Include:
  • 1.7 Who is This Report For?
  • 1.8 Methodology
    • 1.8.1 COVID-19 Impact: Recovery Scenarios
    • 1.8.2 Market Evaluation & Forecasting Methodology
  • 1.9 Frequently Asked Questions (FAQs)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2 Executive Summary

  • 2.1 COVID-19 Vaccine Tracker
  • 2.2 Top Recipients of COVID-19 R&D Funding
  • 2.3 North America Leading the Overall Vaccines Market
  • 2.4 Strong Portfolio has Propelled Sanofi & Pfizer to Dominate the Worldwide Vaccines Market

3 Global Vaccine Sales Market Dynamics

  • 3.1 COVID-19 Impact on the Vaccine Sales Market
  • 3.2 Current Trends in the Vaccine Sales Market
  • 3.3 Market Driving Factors
    • 3.3.1 Rising Focus and Government Support on Immunization Programs
    • 3.3.2 Growing Investment in Vaccine Development
    • 3.3.3 Increasing Company Initiatives to Enhance Vaccine R&D
    • 3.3.4 High Prevalence of Infectious Diseases
    • 3.3.5 Technological Advancements in Vaccine Administration
    • 3.3.6 Rapid Need of Immunization
    • 3.3.7 Strong Supply Backed Up by Robust R&D to Drive the Market
  • 3.4 Market Restraining Factors
    • 3.4.1 Inadequate Reimbursement Coverage
    • 3.4.2 High Cost of Vaccine Development
    • 3.4.3 Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
    • 3.4.4 Stringent Government Regulations for Approval
    • 3.4.5 Inadequate Access to Vaccines
    • 3.4.6 Product Recalls
  • 3.5 Opportunities in the Global Market
    • 3.5.1 High Growth Prospects in Emerging Markets
    • 3.5.2 Focus on Therapeutic Vaccines
    • 3.5.3 Use of Adjuvants in Vaccines
    • 3.5.4 Government Support for Future Vaccine R&D
  • 3.6 SWOT Analysis
    • 3.6.1 Strengths
      • 3.6.1.1 Growing Demand from Emerging Economies
      • 3.6.1.2 Prevention is Better Than Cure
      • 3.6.1.3 Growing Vaccination Awareness to Boost Market Growth
    • 3.6.2 Weaknesses
      • 3.6.2.1 Strong Entry Barriers to Challenge Market Growth
      • 3.6.2.2 Capital Intensive Business
    • 3.6.3 Opportunities
      • 3.6.3.1 Technological Advancements
      • 3.6.3.2 Innovations in Vaccine Market
    • 3.6.4 Threats
      • 3.6.4.1 Maximum Market Share Captured by Few Global Vaccine Manufacturers
      • 3.6.4.2 Productivity Gap
  • 3.7 PEST Analysis

4 Global Vaccine Sales Market Analysis

  • 4.1 Global Market Outlook
  • 4.2 Global Market Size Estimation and Forecast
    • 4.2.1 Pre-COVID-19 Market Scenario
    • 4.2.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

5 Global Vaccine Sales Market Analysis by Region

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 Latin America
  • 5.5 MEA
  • 5.6 Regional Market Size Estimation and Forecast
    • 5.6.1 Pre-COVID-19 Market Scenario
    • 5.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

6 Global Vaccine Sales Market Analysis by Indication

  • 6.1 Segment Overview
  • 6.2 Pneumococcal
  • 6.3 Rotavirus
  • 6.4 Influenza
  • 6.5 Hepatitis
  • 6.6 COVID-19
  • 6.7 Measles
  • 6.8 Mumps & Varicella
  • 6.9 Typhoid
  • 6.10 Meningococcal
  • 6.11 DPT
  • 6.12 Global Market Size Estimation and Forecast by Indication
    • 6.12.1 Pre-COVID-19 Market Scenario
    • 6.12.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

7 Global Vaccine Sales Market Analysis by Route of Administration

  • 7.1 Segment Overview
  • 7.2 Intramuscular
  • 7.3 Subcutaneous
  • 7.4 Oral
  • 7.5 Global Market Size Estimation and Forecast by Route of Administration
    • 7.5.1 Pre-COVID-19 Market Scenario
    • 7.5.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

8 Global Vaccine Sales Market Analysis by Type

  • 8.1 Segment Overview
  • 8.2 Inactivated
  • 8.3 Live Attenuated
  • 8.4 Toxoid
  • 8.5 Recombinant/Conjugate/Subunit
  • 8.6 Global Market Size Estimation and Forecast by Type
    • 8.6.1 Pre-COVID-19 Market Scenario
    • 8.6.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

9 Global Vaccine Sales Market Analysis by Distribution Channel

  • 9.1 Segment Overview
  • 9.2 Hospital & Retail Pharmacies
  • 9.3 Government Suppliers
  • 9.4 Global Market Size Estimation and Forecast by Distribution Channel
    • 9.4.1 Pre-COVID-19 Market Scenario
    • 9.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

10 Global Vaccine Sales Market Analysis by Age Group

  • 10.1 Segment Overview
  • 10.2 Pediatrics
  • 10.3 Adults
  • 10.4 Global Market Size Estimation and Forecast by Age Group
    • 10.4.1 Pre-COVID-19 Market Scenario
    • 10.4.2 Post-COVID-19 Market Scenarios (V, U, W, L Shaped Recovery Analysis

11 North America Vaccine Sales Market

  • 11.1 Introduction
  • 11.2 North America Vaccine Sales Market by Country, Forecast 2022-2032
  • 11.3 North America Vaccine Sales Market Forecast by Indication
  • 11.4 North America Vaccine Sales Market Forecast by Route of Administration
  • 11.5 North America Vaccine Sales Market Forecast by Type
  • 11.6 North America Vaccine Sales Market Forecast by Distribution Channel
  • 11.7 North America Vaccine Sales Market Forecast by Age Group
  • 11.8 U.S. Vaccine Sales Market Forecast, 2022-2032
    • 11.8.1 Introduction
    • 11.8.2 U.S. Vaccine Sales Market Revenue, 2022-2032
    • 11.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Vaccine Sales Market Forecast, 2022-2032
  • 11.9 Canada Vaccine Sales Market Forecast, 2022-2032
    • 11.9.1 Introduction
    • 11.9.2 Canada Vaccine Sales Market Revenue, 2022-2032
    • 11.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Vaccine Sales Market Forecast, 2022-2032

12 Europe Vaccine Sales Market

  • 12.1 Introduction
  • 12.2 Europe Vaccine Sales Market by Country, Forecast 2022-2032
  • 12.3 Europe Vaccine Sales Market Forecast by Indication
  • 12.4 Europe Vaccine Sales Market Forecast by Route of Administration
  • 12.5 Europe Vaccine Sales Market Forecast by Type
  • 12.6 Europe Vaccine Sales Market Forecast by Distribution Channel
  • 12.7 Europe Vaccine Sales Market Forecast by Age Group
  • 12.8 Germany Vaccine Sales Market Forecast, 2022-2032
    • 12.8.1 Germany Well Positioned with an Established Healthcare System
    • 12.8.2 Germany Vaccine Sales Industry Analysis
    • 12.8.3 Germany Vaccine Sales Market Revenue, 2022-2032
    • 12.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Vaccine Sales Market Forecast, 2022-2032
  • 12.9 UK Vaccine Sales Market Forecast, 2022-2032
    • 12.9.1 UK Vaccine Sales Industry Analysis
    • 12.9.2 Technological Advancements to Fuel Market Growth
    • 12.9.3 Need to Invest in Vaccines to Offer Lucrative Growth Opportunities
    • 12.9.4 UK Vaccine Sales Market Revenue, 2022-2032
    • 12.9.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Vaccine Sales Market Forecast, 2022-2032
  • 12.10 France Vaccine Sales Market Forecast, 2022-2032
    • 12.10.1 France Vaccine Sales Industry Analysis
    • 12.10.2 France Vaccine Sales Market Revenue, 2022-2032
    • 12.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Vaccine Sales Market Forecast, 2022-2032
  • 12.11 Italy Vaccine Sales Market Forecast, 2022-2032
    • 12.11.1 Italy Vaccine Sales Industry Analysis
    • 12.11.2 Italy Vaccine Sales Market Revenue, 2022-2032
    • 12.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Vaccine Sales Market Forecast, 2022-2032
  • 12.12 Spain Vaccine Sales Market Forecast, 2022-2032
    • 12.12.1 Spain Vaccine Sales Market Revenue, 2022-2032
    • 12.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Vaccine Sales Market Forecast, 2022-2032
  • 12.13 Russia Vaccine Sales Market Forecast, 2022-2032
    • 12.13.1 Impact on Sputnik V Due to Russia Invasion of Ukraine
    • 12.13.2 Russia Vaccine Sales Market Revenue, 2022-2032
    • 12.13.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Russia Vaccine Sales Market Forecast, 2022-2032
  • 12.14 Rest of Europe Vaccine Sales Market Forecast, 2022-2032
    • 12.14.1 Rest of Europe Vaccine Sales Market Revenue, 2022-2032
    • 12.14.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Vaccine Sales Market Forecast, 2022-2032

13 Asia Pacific Vaccine Sales Market

  • 13.1 Introduction
  • 13.2 Asia Pacific Vaccine Sales Market by Country, Forecast 2022-2032
  • 13.3 Asia Pacific Vaccine Sales Market Forecast by Indication
  • 13.4 Asia Pacific Vaccine Sales Market Forecast by Route of Administration
  • 13.5 Asia Pacific Vaccine Sales Market Forecast by Type
  • 13.6 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel
  • 13.7 Asia Pacific Vaccine Sales Market Forecast by Age Group
  • 13.8 Japan Vaccine Sales Market Forecast, 2022-2032
    • 13.8.1 Japan Vaccine Sales Industry Analysis
    • 13.8.2 Japan Vaccine Sales Market Revenue, 2022-2032
    • 13.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Vaccine Sales Market Forecast, 2022-2032
  • 13.9 China Vaccine Sales Market Forecast, 2022-2032
    • 13.9.1 China Vaccine Sales Industry Analysis
    • 13.9.2 China Vaccine Sales Market Revenue, 2022-2032
    • 13.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Vaccine Sales Market Forecast, 2022-2032
  • 13.10 India Vaccine Sales Market Forecast, 2022-2032
    • 13.10.1 India Vaccine Sales Industry Analysis
    • 13.10.2 Indian Vaccines Industry Has a Huge Internal Market to be Serviced
    • 13.10.3 Research and Development in India for Vaccines Innovation and Invention
    • 13.10.4 India Vaccine Sales Market Revenue, 2022-2032
    • 13.10.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Vaccine Sales Market Forecast, 2022-2032
  • 13.11 Australia Vaccine Sales Market Forecast, 2022-2032
    • 13.11.1 Australia Vaccine Sales Industry Analysis
    • 13.11.2 Australia Vaccine Sales Market Revenue, 2022-2032
    • 13.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Australia Vaccine Sales Market Forecast, 2022-2032
  • 13.12 Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032
    • 13.12.1 Rest of Asia Pacific Vaccine Sales Market Revenue, 2022-2032
    • 13.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032

14 Latin America Vaccine Sales Market

  • 14.1 Introduction
  • 14.2 Latin America Vaccine Sales Market by Country, Forecast 2022-2032
  • 14.3 Latin America Vaccine Sales Market Forecast by Indication
  • 14.4 Latin America Vaccine Sales Market Forecast by Route of Administration
  • 14.5 Latin America Vaccine Sales Market Forecast by Type
  • 14.6 Latin America Vaccine Sales Market Forecast by Distribution Channel
  • 14.7 Latin America Vaccine Sales Market Forecast by Age Group
  • 14.8 Brazil Vaccine Sales Market Forecast, 2022-2032
    • 14.8.1 Brazil Vaccine Sales Industry Analysis
    • 14.8.2 Public Market Accounts for 90% of Demand
    • 14.8.3 PAHO Announced 2 Centers in Argentina and Brazil as Regional Hubs for Development of mRNA-based Vaccine Manufacturing
    • 14.8.4 Brazil Vaccine Sales Market Revenue, 2022-2032
    • 14.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Vaccine Sales Market Forecast, 2022-2032
  • 14.9 Mexico Vaccine Sales Market Forecast, 2022-2032
    • 14.9.1 Mexico Vaccine Sales Industry Analysis
    • 14.9.2 Emerging Region Across Latin America
    • 14.9.3 Mexico Vaccine Sales Market Revenue, 2022-2032
    • 14.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Vaccine Sales Market Forecast, 2022-2032
  • 14.10 Rest of Latin America Vaccine Sales Market Forecast, 2022-2032
    • 14.10.1 Rest of Latin America Vaccine Sales Market Revenue, 2022-2032
    • 14.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Vaccine Sales Market Forecast, 2022-2032

15 Middle East and Africa Vaccine Sales Market

  • 15.1 Introduction
  • 15.2 Middle East and Africa Vaccine Sales Market by Country, Forecast 2022-2032
  • 15.3 Middle East and Africa Vaccine Sales Market Forecast by Indication
  • 15.4 Middle East and Africa Vaccine Sales Market Forecast by Route of Administration
  • 15.5 Middle East and Africa Vaccine Sales Market Forecast by Type
  • 15.6 Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel
  • 15.7 Middle East and Africa Vaccine Sales Market Forecast by Age Group
  • 15.8 GCC Vaccine Sales Market Forecast, 2022-2032
    • 15.8.1 GCC Vaccine Sales Industry Analysis
    • 15.8.2 Gulf Nations Have United to Support COVAX
    • 15.8.3 GCC Vaccine Sales Market Revenue, 2022-2032
    • 15.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Vaccine Sales Market Forecast, 2022-2032
  • 15.9 South Africa Vaccine Sales Market Forecast, 2022-2032
    • 15.9.1 COVAX Delivering Vaccines to Africa
    • 15.9.2 South Africa Vaccine Sales Industry Analysis
    • 15.9.3 South Africa Vaccine Sales Market Revenue, 2022-2032
    • 15.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Vaccine Sales Market Forecast, 2022-2032
  • 15.10 Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032
    • 15.10.1 Rest of Middle East and Africa Vaccine Sales Market Revenue, 2022-2032
    • 15.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032

16 Company Profiles

  • 16.1 Bavarian Nordic
    • 16.1.1 Company Snapshot
    • 16.1.2 Company Overview
    • 16.1.3 Financial Analysis
      • 16.1.3.1 Net Revenue, 2015-2020
      • 16.1.3.2 R&D Expenses, 2015-2020
      • 16.1.3.3 Gross Profit, 2015-2020
    • 16.1.4 Product Benchmarking
    • 16.1.5 Recent Developments till December 2021
  • 16.2 Bharat Biotech
    • 16.2.1 Company Snapshot
    • 16.2.2 Company Overview
    • 16.2.3 Product Benchmarking
    • 16.2.4 Recent Developments till December 2021
  • 16.3 CSL Limited
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Financial Analysis
      • 16.3.3.1 Net Revenue, 2015-2020
      • 16.3.3.2 R&D Expenses, 2015-2020
      • 16.3.3.3 Gross Profit, 2015-2020
    • 16.3.4 Product Benchmarking
    • 16.3.5 Recent Developments till December 2021
  • 16.4 Emergent BioSolutions Inc.
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Net Revenue, 2015-2020
      • 16.4.3.2 R&D Expenses, 2015-2020
      • 16.4.3.3 Gross Profit, 2015-2020
    • 16.4.4 Product Benchmarking
    • 16.4.5 Recent Developments till December 2021
  • 16.5 GlaxoSmithKline plc
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Net Revenue, 2015-2020
      • 16.5.3.2 R&D Expenses, 2015-2020
      • 16.5.3.3 Gross Profit, 2015-2020
    • 16.5.4 Product Benchmarking
    • 16.5.5 Recent Developments till December 2021
  • 16.6 Inovio Pharmaceuticals, Inc.
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2015-2020
      • 16.6.3.2 R&D Expenses, 2015-2020
      • 16.6.3.3 Gross Profit, 2015-2020
    • 16.6.4 Product Benchmarking
    • 16.6.5 Recent Developments till December 2021
  • 16.7 J&J
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Net Revenue, 2015-2020
      • 16.7.3.2 R&D Expenses, 2015-2020
      • 16.7.3.3 Gross Profit, 2015-2020
    • 16.7.4 Product Benchmarking
    • 16.7.5 Recent Developments till December 2021
  • 16.8 Merck Co., Inc.
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Financial Analysis
      • 16.8.3.1 Net Revenue, 2015-2020
      • 16.8.3.2 R&D Expenses, 2015-2020
      • 16.8.3.3 Gross Profit, 2015-2020
    • 16.8.4 Product Benchmarking
    • 16.8.5 Recent Developments till December 2021
  • 16.9 Mitsubishi Tanabe Pharma Corporation
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Product Benchmarking
    • 16.9.4 Recent Developments till December 2021
  • 16.10 Moderna, Inc.
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Net Revenue, 2015-2020
      • 16.10.3.2 R&D Expenses, 2015-2020
      • 16.10.3.3 Gross Profit, 2015-2020
    • 16.10.4 Product Benchmarking
    • 16.10.5 Recent Developments till December 2021
  • 16.11 Novavax
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Net Revenue, 2015-2020
      • 16.11.3.2 R&D Expenses, 2015-2020
      • 16.11.3.3 Gross Profit, 2015-2020
    • 16.11.4 Product Benchmarking
    • 16.11.5 Recent Developments till December 2021
  • 16.12 Panacea Biotec Ltd.
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Product Benchmarking
  • 16.13 Pfizer Inc.
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Financial Analysis
      • 16.13.3.1 Net Revenue, 2015-2020
      • 16.13.3.2 R&D Expenses, 2015-2020
      • 16.13.3.3 Gross Profit, 2015-2020
    • 16.13.4 Product Benchmarking
    • 16.13.5 Recent Developments till December 2021
  • 16.14 Sanofi
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Financial Analysis
      • 16.14.3.1 Net Revenue, 2015-2020
      • 16.14.3.2 R&D Expenses, 2015-2020
      • 16.14.3.3 Gross Profit, 2015-2020
    • 16.14.4 Product Benchmarking
    • 16.14.5 Recent Developments till December 2021
  • 16.15 Serum Institute of India Pvt. Ltd.
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Product Benchmarking
    • 16.15.4 Recent Developments till December 2021
  • 16.16 AstraZeneca PLC
    • 16.16.1 Company Snapshot
    • 16.16.2 Company Overview
    • 16.16.3 Financial Analysis
      • 16.16.3.1 Net Revenue, 2015-2020
      • 16.16.3.2 R&D Expenses, 2015-2020
      • 16.16.3.3 Gross Profit, 2015-2020
    • 16.16.4 Product Benchmarking
    • 16.16.5 Recent Developments till December 2021
  • 16.17 Sinopharm
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Product Benchmarking
  • 16.18 SINOVAC
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Financial Analysis
      • 16.18.3.1 Net Revenue, 2015-2020
      • 16.18.3.2 R&D Expenses, 2015-2020
      • 16.18.3.3 Gross Profit, 2015-2020
    • 16.18.4 Product Benchmarking
    • 16.18.5 Recent Developments till December 2021
  • 16.19 Takeda Pharmaceutical Company Limited
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.3 Financial Analysis
      • 16.19.3.1 Net Revenue, 2015-2020
      • 16.19.3.2 R&D Expenses, 2015-2020
      • 16.19.3.3 Gross Profit, 2015-2020
    • 16.19.4 Product Benchmarking
    • 16.19.5 Recent Developments till December 2021
  • 16.20 Daiichi Sankyo Co., Ltd.
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Financial Analysis
      • 16.20.3.1 Net Revenue, 2015-2020
      • 16.20.3.2 R&D Expenses, 2015-2020
      • 16.20.3.3 Gross Profit, 2015-2020
    • 16.20.4 Product Benchmarking
    • 16.20.5 Recent Developments till December 2021

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks
  • 17.2 Recommendations

List of Tables

  • Table 1: Global Vaccine Sales Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
  • Table 2: Global COVID-19 Vaccine Tracker by Company & Vaccine Type
  • Table 3: Vaccine Sales Market 2022 - 2032
  • Table 4: Vaccine Sales Market Forecast, 2022 - 2032: "V" Shaped Recovery
  • Table 5: Vaccine Sales Market Forecast, 2022 - 2032: "U" Shaped Recovery
  • Table 6: Vaccine Sales Market Forecast, 2022 - 2032: "W" Shaped Recovery
  • Table 7: Vaccine Sales Market Forecast, 2022 - 2032: "L" Shaped Recovery
  • Table 8: Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 9: Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 10: Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 11: Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 12: Global Vaccine Sales Market Forecast by Region, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 13: Vaccine Types
  • Table 14: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 15: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 16: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 17: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 18: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 19: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 20: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 21: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 22: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 23: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 24: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 25: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 26: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 27: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 28: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 29: Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 30: Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 31: Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 32: Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 33: Global Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 34: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 35: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 36: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 37: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 38: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 39: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 40: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 41: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 42: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 43: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 44: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 45: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 46: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 47: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 48: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 49: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 50: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 51: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 52: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 53: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 54: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 55: North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 56: North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 57: North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 58: North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 59: North America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 60: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 61: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 62: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 63: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 64: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 65: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 66: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 67: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 68: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 69: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 70: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 71: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 72: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 73: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 74: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 75: Europe Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 76: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 77: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 78: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 79: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 80: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 81: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 82: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 83: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 84: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 85: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 86: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 87: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 88: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 89: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 90: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 91: Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 92: Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 93: Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 94: Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 95: Europe Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 96: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 97: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 98: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 99: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 100: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 101: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 102: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 103: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 104: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 105: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 106: UK Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 107: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 108: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 109: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 110: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 111: France Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 112: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 113: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 114: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 115: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 116: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 117: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 118: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 119: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 120: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 121: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 122: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 123: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 124: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 125: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 126: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 127: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 128: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 129: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 130: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 131: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 132: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 133: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 134: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 135: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 136: Asia Pacific Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 137: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 138: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 139: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 140: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 141: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 142: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 143: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 144: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 145: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 146: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 147: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 148: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 149: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 150: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 151: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 152: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 153: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 154: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 155: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 156: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 157: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 158: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 159: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 160: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 161: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 162: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 163: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 164: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 165: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 166: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 167: China Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 168: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 169: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 170: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 171: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 172: India Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 173: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 174: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 175: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 176: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 177: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 178: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 179: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 180: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 181: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 182: Rest of APAC Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 183: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 184: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 185: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 186: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 187: Latin America Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 188: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 189: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 190: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 191: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 192: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 193: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 194: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 195: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 196: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 197: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 198: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 199: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 200: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 201: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 202: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 203: Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 204: Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 205: Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 206: Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 207: Latin America Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 208: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 209: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 210: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 211: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 212: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 213: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 214: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 215: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 216: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 217: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 218: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 219: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 220: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 221: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 222: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 223: Rest of LATAM Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 224: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 225: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 226: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 227: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 228: MEA Vaccine Sales Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 229: MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 230: MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 231: MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 232: MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 233: MEA Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 234: MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 235: MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 236: MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 237: MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 238: MEA Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 239: MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 240: MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 241: MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 242: MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 243: MEA Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 244: MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 245: MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 246: MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 247: MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 248: MEA Vaccine Sales Market Forecast by Distribution Channel , 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 249: MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%)
  • Table 250: MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 251: MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 252: MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 253: MEA Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 254: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 255: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 256: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 257: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 258: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 259: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 260: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 261: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 262: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 263: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 264: Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
  • Table 265: Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 266: Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 267: Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 268: Rest of MEA Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 269: Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 270: Bavarian Nordic: Product Benchmarking
  • Table 271: Bavarian Nordic: Recent Developments till December 2021
  • Table 272: Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 273: Bharat Biotech: Product Benchmarking
  • Table 274: Bharat Biotech: Recent Developments till December 2021
  • Table 275: CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 276: CSL Limited: Product Benchmarking
  • Table 277: CSL Limited: Recent Developments till December 2021
  • Table 278: Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 279: Emergent BioSolutions Inc.: Product Benchmarking
  • Table 280: Emergent BioSolutions Inc.: Recent Developments till December 2021
  • Table 281: GlaxoSmithKline plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 282: GlaxoSmithKline plc: Product Benchmarking
  • Table 283: GlaxoSmithKline plc: Recent Developments till December 2021
  • Table 284: Inovio Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 285: Inovio Pharmaceuticals, Inc.: Product Benchmarking
  • Table 286: Inovio Pharmaceuticals, Inc.: Recent Developments till December 2021
  • Table 287: J&J: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 288: J&J: Product Benchmarking
  • Table 289: J&J: Recent Developments till December 2021
  • Table 290: Merck Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 291: Merck Co., Inc.: Product Benchmarking
  • Table 292: Merck Co., Inc.: Recent Developments till December 2021
  • Table 293: Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 294: Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
  • Table 295: Mitsubishi Tanabe Pharma Corporation: Recent Developments till December 2021
  • Table 296: Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 297: Moderna, Inc.: Product Benchmarking
  • Table 298: Moderna, Inc.: Recent Developments till December 2021
  • Table 299: Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 300: Novavax: Product Benchmarking
  • Table 301: Novavax: Recent Developments till December 2021
  • Table 302: Panacea Biotec Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 303: Panacea Biotec Ltd.: Product Benchmarking
  • Table 304: Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 305: Pfizer Inc.: Product Benchmarking
  • Table 306: Pfizer Inc.: Recent Developments till December 2021
  • Table 307: Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 308: Sanofi: Product Benchmarking
  • Table 309: Sanofi: Recent Developments till December 2021
  • Table 310: Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 311: Serum Institute of India Pvt. Ltd.: Product Benchmarking
  • Table 312: Serum Institute of India Pvt. Ltd.: Recent Developments till December 2021
  • Table 313: AstraZeneca PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 314: AstraZeneca PLC: Product Benchmarking
  • Table 315: AstraZeneca PLC: Recent Developments till December 2021
  • Table 316: Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 317: Sinopharm: Product Benchmarking
  • Table 318: SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 319: SINOVAC: Product Benchmarking
  • Table 320: SINOVAC: Recent Developments till December 2021
  • Table 321: Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 322: Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 323: Takeda Pharmaceutical Company Limited: Recent Developments till December 2021
  • Table 324: Daiichi Sankyo Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 325: Daiichi Sankyo Co., Ltd.: Product Benchmarking
  • Table 326: Daiichi Sankyo Co., Ltd.: Recent Developments till December 2021

List of Figures

  • Figure 1: Global Vaccine Sales Market: Market Segmentation
  • Figure 2: Top Recipients of COVID-19 R&D Funding in US$ million (As of March 2021)
  • Figure 3: Global Vaccine Sales Market Trends
  • Figure 1: Global Vaccine Sales Market: SWOT Analysis
  • Figure 2: PEST Analysis
  • Figure 3: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 4: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 5: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 6: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 7 : lobal Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 8 : lobal Vaccine Sales Market Share Forecast by Region 2022, 2027, 2032 (%)
  • Figure 9 : lobal Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 10: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 11: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 12: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 13: Global Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 14: Global Vaccine Sales Market Share Forecast by Indication: 2022, & 2032 (%)
  • Figure 15: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 16: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 17: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 18: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 19: Global Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 20: Global Vaccine Sales Market Share Forecast by Route of Administration: 2022, 2027, 2032 (%)
  • Figure 21: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 22: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 23: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 24: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 25: Global Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 26: Global Vaccine Sales Market Share Forecast by Type: 2022, 2027, 2032 (%)
  • Figure 27: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 28: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 29: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 30: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 31: Global Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 32: Global Vaccine Sales Market Share Forecast by Distribution Channel: 2022, 2027, 2032 (%)
  • Figure 33: Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 34: Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 35: Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 36: Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 37: Global Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 38: Global Vaccine Sales Market Share Forecast by Age Group: 2022, 2027, 2032 (%)
  • Figure 39: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 40: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 41: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 42: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 43: Global Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 44: North America Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
  • Figure 45: North America Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
  • Figure 46: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 47: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 48: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 49: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 50: North America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 51: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 52: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 53: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 54: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 55: North America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 56: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 57: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 58: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 59: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 60: North America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 61: North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 62: North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 63: North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 64: North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 65: North America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 66: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 67: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 68: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 69: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 70: North America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 71: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 72: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 73: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 74: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 75: U.S. Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 76: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 77: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 78: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 79: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 80: Canada Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 81: Europe Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
  • Figure 82: Europe Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
  • Figure 83: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 84: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 85: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 86: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 87: Europe Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 88: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 89: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 90: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 91: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 92: Europe Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 93: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 94: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 95: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 96: Europe Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 97 : urope Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 98 : urope Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 99 : urope Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 100: Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 101: Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 102: Europe Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 103: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 104: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 105: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 106: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 107: Europe Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 108: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 109: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 110: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 111: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 112: Germany Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 113: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 114: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 115: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 116: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 117: UK Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 118: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 119: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 120: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 121: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 122: France Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 123: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 124: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 125: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 126: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 127: Italy Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 128: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 129: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 130: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 131: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 132: Spain Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 133: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 134: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 135: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 136: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 137: Russia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 138: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 139: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 140: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 141: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 142: Rest of Europe Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 143: Asia Pacific Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
  • Figure 144: Asia Pacific Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
  • Figure 145: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 146: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 147: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 148: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 149: Asia Pacific Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 150: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 151: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 152: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 153: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 154: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 155: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 156: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 157: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 158: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 159: Asia Pacific Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 160: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 161: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 162: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 163: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 164: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 165: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 166: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 167: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 168: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 169: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 170: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 171: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 172: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 173: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 174: Japan Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 175: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 176: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 177: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 178: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 179: China Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 180: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 181: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 182: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 183: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 184: India Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 185: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 186: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 187: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 188: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 189: Australia Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 190: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 191: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 192: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 193: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 194: Rest of Asia Pacific Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 195: Latin America Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
  • Figure 196: Latin America Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
  • Figure 197: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 198: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 199: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 200: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 201: Latin America Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 202: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 203: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 204: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 205: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 206: Latin America Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 207: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 208: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 209: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 210: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 211: Latin America Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 212: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 213: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 214: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 215: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 216: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 217: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 218: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 219: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 220: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 221: Latin America Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 222: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 223: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 224: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 225: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 226: Brazil Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 227: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 228: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 229: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 230: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 231: Mexico Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 232: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 233: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 234: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 235: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 236: Rest of Latin America Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 237: Middle East and Africa Vaccine Sales Market Forecast by Country 2022-2032 (US$ million)
  • Figure 238: Middle East and Africa Vaccine Sales Market Share Forecast by Country 2022, 2027, 2032 (%)
  • Figure 239: Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %)
  • Figure 240: Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 241: Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 242: Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 243: Middle East and Africa Vaccine Sales Market Forecast by Indication, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 244: Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
  • Figure 245: Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 246: Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 247: Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 248: Middle East and Africa Vaccine Sales Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 249: Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
  • Figure 250: Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 251: Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 252: Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 253: Middle East and Africa Vaccine Sales Market Forecast by Type, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 254: Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 255: Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 256: Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 257: Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 258: Middle East and Africa Vaccine Sales Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 259: Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
  • Figure 260: Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 261: Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 262: Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 263: Middle East and Africa Vaccine Sales Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 264: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 265: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 266: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 267: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 268: GCC Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 269: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 270: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 271: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 272: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 273: South Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 274: Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 275: Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "V" Shaped Recovery
  • Figure 276: Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "U" Shaped Recovery
  • Figure 277: Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "W" Shaped Recovery
  • Figure 278: Rest of Middle East and Africa Vaccine Sales Market Forecast, 2022-2032 (US$ billion, AGR %): "L" Shaped Recovery
  • Figure 279: Bavarian Nordic: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 280: Bavarian Nordic: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 281: Bavarian Nordic: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 282: CSL Limited: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 283: CSL Limited: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 284: CSL Limited: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 285: Emergent BioSolutions Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 286: Emergent BioSolutions Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 287: Emergent BioSolutions Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 288: GlaxoSmithKline plc: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 289: GlaxoSmithKline plc: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 290: GlaxoSmithKline plc: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 291: Inovio Pharmaceuticals, Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 292: Inovio Pharmaceuticals, Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 293: Inovio Pharmaceuticals, Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 294: J&J: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 295: J&J: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 296: J&J: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 297: Merck Co., Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 298: Merck Co., Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 299: Merck Co., Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 300: Moderna, Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 301: Moderna, Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 302: Moderna, Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 303: Novavax: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 304: Novavax: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 305: Novavax: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 306: Pfizer Inc.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 307: Pfizer Inc.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 308: Pfizer Inc.: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 309: Sanofi: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 310: Sanofi: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 311: Sanofi: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 312: AstraZeneca PLC: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 313: AstraZeneca PLC: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 314: AstraZeneca PLC: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 315: SINOVAC: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 316: SINOVAC: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 317: SINOVAC: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 318: Takeda Pharmaceutical Company Limited: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 319: Takeda Pharmaceutical Company Limited: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 320: Takeda Pharmaceutical Company Limited: Gross Profit, 2015-2020 (US$ billion, AGR %)
  • Figure 321: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2020 (US$ billion, AGR %)
  • Figure 322: Daiichi Sankyo Co., Ltd.: R&D Expenses, 2015-2020 (US$ billion, AGR %)
  • Figure 323: Daiichi Sankyo Co., Ltd.: Gross Profit, 2015-2020 (US$ billion, AGR %)

Companies Profiled in the Report:

  • AstraZeneca PLC
  • Bavarian Nordic
  • Bharat Biotech
  • CSL Limited
  • Daiichi Sankyo Co.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • J&J
  • Merck Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm
  • SINOVAC
  • Takeda Pharmaceutical Company Limited
  • List of Other Companies
  • Abeona Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Autolus
  • AveXis
  • BioCancell
  • Biomay
  • Biomiga
  • BioReliance
  • Biotec Services International
  • Celladon
  • Cellectis
  • Cellular Biomedicine Group
  • Delphi Genetics
  • Department of Neuroscience, University of Minnesota
  • Desktop Genetics
  • DNAtrix
  • Elixirgen Scientific
  • Epeius Biotechnologies
  • EUFETS
  • Eurofins Genomics
  • European Society of Gene and Cell Therapy
  • GEG Tech
  • Genable Technologies
  • Immune Design
  • Immune Technology
  • ImmunoGenes
  • Immunomic Therapeutics
  • Inbiomed
  • Indiana University Vector Production Facility
  • VIVEbiotech
  • Voyager Therapeutics
  • Waisman Biomanufacturing
  • Xpress Biologics

List of Organizations:

  • Association of British Pharmaceutical Industry (ABPI)
  • Central Drugs Standard Control Organization (CDSCO)
  • Department of Health and Family Welfare
  • Development and Reform Commission (NDRC)
  • European Commission
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Indian Drug Manufacturer's Association (IDMA)
  • International Society of Pharmaceutical Engineering (IPSE)
  • Korea Food and Drug Administration (KFDA)
  • Korea Pharmaceutical Manufacturer's Association (KPMA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines Manufacturing Industry Partnership (MMIP)
  • Ministry of Health (MOH)
  • Ministry of Health, Labor and Welfare (MHLW)
  • Ministry of Industry and Information Technology (MIIT)
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • World Health Organization (WHO)